These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8952896)

  • 1. [Resistance to antineoplastic treatments: mechanisms, clinical value].
    Bonnal C; Calvo F
    C R Seances Soc Biol Fil; 1996; 190(4):455-66. PubMed ID: 8952896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance and its reversal.
    Volm M
    Anticancer Res; 1998; 18(4C):2905-17. PubMed ID: 9713485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular mechanisms of multidrug resistance of tumor cells.
    Stavrovskaya AA
    Biochemistry (Mosc); 2000 Jan; 65(1):95-106. PubMed ID: 10702644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of drug resistance in cancer chemotherapy.
    Luqmani YA
    Med Princ Pract; 2005; 14 Suppl 1():35-48. PubMed ID: 16103712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
    Redmond SM; Joncourt F; Buser K; Ziemiecki A; Altermatt HJ; Fey M; Margison G; Cerny T
    Cancer Res; 1991 Apr; 51(8):2092-7. PubMed ID: 1672623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
    Luan YZ; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of antifolate resistance.
    Assaraf YG
    Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Messenger RNA expression of resistance factors in human tumor cell lines after single exposure to radiation.
    Stammler G; Pommerenke EW; Masanek U; Mattern J; Volm M
    J Exp Ther Oncol; 1996 Jan; 1(1):39-48. PubMed ID: 9414387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
    Zhang J; Tian Q; Chan SY; Duan W; Zhou S
    Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell drug resistance and its reversal.
    Mansouri A; Henle KJ; Nagle WA; Moss AJ
    SAAS Bull Biochem Biotechnol; 1990 Jan; 3():91-6. PubMed ID: 1366508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance of hematologic neoplasm cells to cytostatics. Part II].
    Kodydková K; Krejsek J
    Cas Lek Cesk; 2000 Sep; 139(19):591-5. PubMed ID: 11192750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemosensitization of solid tumors by modulation of resistance mechanisms.
    Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T
    Curr Opin Investig Drugs; 2002 Apr; 3(4):634-40. PubMed ID: 12090736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
    Elliott T; Sethi T
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges.
    Zhang D; Fan D
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1369-78. PubMed ID: 17944563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.